Siemens to build molecular centre in Abu Dhabi
Mubadala Development Company has signed a contract with Siemens Medical Solutions to build and operate a specialist Molecular Imaging Center (MIC) in Abu Dhabi.
The centre will include the Siemens PET CT (Positron Emission Tomography - Computed Tomography) diagnostic system and the Cyclotron radioisotope delivery system.
.The $21.7 million three-phased contract entails designing, building, and operation and maintenance of the MIC. Scheduled to open during the second half of 2008, the facility will be the first of its kind in the region.
Mubadala is an investment and development vehicle wholly owned by the Government of the Emirates of Abu Dhabi.
The first phase began in 2006 and saw Siemens setting up a team of experts who have been working closely with Mubadala to design what will be a unique facility with the very latest and innovative molecular imaging diagnostic technology.
The contract signing marks the move into the second phase of the project, when the building of the MIC will commence.
A five-year facility management and operation contract is expected to be signed following completion of the facility construction.
The MIC will also be the first in this region to feature a Cyclotron, Siemens' particle accelerator that produces high yields of reliable radioisotope bio markers. These are essential for accurate PET diagnosis.
In addition to supplying Mubadala's Molecular Imaging Centre, the plan is to enable other diagnostic facilities in the vicinity to also have access to this important technology.
As well as the clinical provisions, the company's standard operating system and user interface Syngo will allow seamless data sharing across all parts of the MIC and with other clinics worldwide.
The centre will be fully equipped with state-of-the-art medical diagnostic equipment for anatomic and functional diagnosis. These include the Siemens PET CT (Positron Emission Tomography - Computed Tomography) diagnostic system and the Cyclotron radioisotope delivery system.
Source
No comments:
Post a Comment